



High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future

Guest Editors:

Dr. Joan Carles Escolà-Gil

Institut d'Investigacions
Biomèdiques (IIB) Sant Pau,
CIBER de Diabetes y
Enfermedades Metabólicas
Asociadas (CIBERDEM),
Barcelona, Spain

jescola@santpau.cat

Dr. Josep Julve

Institut d'Investigacions
Biomèdiques (IIB) Sant Pau,
CIBER de Diabetes y
Enfermedades Metabólicas
Asociadas (CIBERDEM),
Barcelona, Spain

JJulve@santpau.cat

Deadline for manuscript
submissions:

closed (10 December 2019)

Message from the Guest Editors

Dear colleagues,

Low HDL cholesterol levels are associated with increased atherosclerotic cardiovascular disease. However, HDL-targeted drugs have failed to reduce cardiovascular events in clinical trials, thereby casting doubt on the beneficial effects of raising HDL levels. HDL has significant cardioprotective functions, including the enhancement of macrophage reverse cholesterol transport and endothelial function, and antioxidant, anti-inflammatory and anti-thrombotic properties. HDL is highly heterogeneous and carries a variety of lipids, proteins and microRNAs. HDL composition is directly related to their cardioprotective functions, but the assignment of specific molecules to HDL functions is not completely understood. Current research is moving towards both the development of robust HDL function tests and the identification of specific HDL molecules within HDL that can be widely applied in translational and pre-clinical studies. The application of novel therapeutic HDL-based approaches requires the development of validated and reproducible measures of these key atheroprotective HDL functions.

Dr. Joan Carles Escolà-Gil

Dr. Josep Julve

Guest Editors





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Charles Brennan

Prof. Dr. Andreas Taubert

Prof. Dr. Kurt A. Jellinger

Prof. Dr. Ian A. Nicholls

Dr. Stephen A. Bustin

Assoc. Prof. Dr. Xiaofeng Jia

Prof. Dr. Maurizio Battino

Prof. Dr. Guido R.M.M. Haenen

Prof. Dr. Setsuko Komatsu

Prof. Dr. Claudiu T. Supuran

Prof. Dr. Irmgard Tegeder

Message from the Editorial Board

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the **Science Citation Index Expanded** (Web of Science), MEDLINE (PubMed), Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2019).

Contact Us

*International Journal of Molecular
Sciences*
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
@IJMS_MDPI